Table 1 Baseline demographic and clinical characteristics of the study population.
Subjects N = 32 | |
|---|---|
Demographics | |
Gender, n (%) | |
Female | 21 (65.6) |
Male | 11 (34.4) |
Age, years | |
Mean ± SD | 37.1 ± 15.8 |
Median (min–max) | 40.5 (10–66) |
≤ 18 years, n (%) | 7 (21.9) |
Associated symptomsa, n (%) | |
Constipation | 18 (56.3) |
Diarrhea | 6 (18.8) |
Attention disorder | 25 (78.1) |
Sleep disorder | 26 (81.3) |
Concomitant treatments b, n (%) | |
Analgesic treatments | 27 (84.4) |
Tramadol | 17 (53.1) |
NSAID | 12 (37.5) |
Morphine | 5 (15.6) |
Paracetamol | 4 (12.5) |
Lamaline | 3 (9.4) |
Codeine | 1 (3.1) |
Other | 10 (31.3) |
Antidepressants (SSRI) | 3 (9.4) |
Antiepileptics | 4 (12.5) |
NRS pain score | |
Total score (mean ± SD) | 7.06 ± 1.22 |
Biological parameters (mean ± SD concentrations) | |
Noradrenaline (nmol/L) | 3.64 ± 2.72 |
Serotonin (µmol/L) | |
Adults c (n = 21) | 0.86 ± 0.37 |
Subjects ≤ 18 years (n = 6) | 0.85 ± 0.28 |
Dopamine (nmol/L) | 0.22 ± 0.12 |
Tryptophan (µmol/L) | 49.48 ± 11.82 |
Kynurenine (µmol/L) | 1.70 ± 0.67 |
IDO1 (%) | 4.09 ± 4.69 |
Tryptase (µg/L) | 6.00 ± 4.85 |
